Real-world efficacy of direct-acting antiviral therapy for HCV infection affecting people who inject drugs delivered in a multidisciplinary setting

Open Forum Infectious Diseases

Volumn 5, Issue 6, 2018, Pages

  Alimohammadi, Arshia ^a   Holeksa, Julie ^a   Thiam, Astou ^a   Truong, David ^a   Conway, Brian ^a  

^a VANCOUVER INFECTIOUS DISEASES CENTRE   (Canada)

Author keywords

Hepatitis C virus; Interferon free direct acting antiviral therapy; Multidisciplinary; PWID

Indexed keywords

AMPHETAMINE; COCAINE; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR PLUS GRAZOPREVIR; GLECAPREVIR PLUS PIBRENTASVIR; LEDIPASVIR PLUS SOFOSBUVIR; METHADONE; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DRUG EFFICACY; DRUG WITHDRAWAL; ELASTOGRAPHY; FEMALE; FOLLOW UP; GENOTYPE; HEALTH INSURANCE; HEPATITIS C; HUMAN; INJECTION DRUG USER; INTENTION TO TREAT ANALYSIS; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OPIATE SUBSTITUTION TREATMENT; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VIREMIA;

EID: 85055032547     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofy120     Document Type: Article

References (29)

1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2:161-76.
2. Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health 2017; 5:e1192-207.
3. Alavi M, Raffa JD, Deans GD, et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int 2014; 34:1198-206.
4. Bennett JE. Infectious diseases and their etiological agents. In: John E, Dolin R, Blaser MJ, Douglas RG, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, PA: Elsevier/Saunders; 2015; 34:2157-2187.
5. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014; 312:631-40.
6. Grebely J, Hajarizadeh B, Dore GJ. Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol 2017; 14(11):641-51.
7. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med 2017; 166:637-48.
8. Centers for Disease Control and Prevention. Testing for HCV infection: an update of guidance for clinicians and laboratories. MMWR Morb Mortal Wkly Rep 2013; 62:362-5.
9. Grebely J, Litwin A, Dore GJ. Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all. J Viral Hepat 2016; 23:664-6.
10. Barua S, Greenwald R, Grebely J, et al. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015; 163:215-23.
11. Marshall AD, Nielsen S, Cunningham EB, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe. J Hepatol 2017; 66:S95-96.
12. Read P, Lothian R, Chronister K, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy 2017; 47:209-15.
13. Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007; 18:437-43.
14. Alimohammadi A, Singh A, Raycraft T, et al. Reduced HCV recurrent viremia in people who inject drugs (PWID) after treatment induced HCV cure. Int J Adv Res 2017; 6:2075-7.
15. Bansal S, Singal AK, McGuire BM, Anand BS. Impact of all oral anti-hepatitis C virus therapy: a meta-analysis. World J Hepatol 2015; 7:806-13.
16. The Lancet. Towards elimination of viral hepatitis by 2030. Lancet 2016; 388(10042):308.
17. Zoulim F, Liang TJ, Gerbes AL, et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut 2015; 64:1824-33.
18. EASL. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017; 66:153-94.
19. AASLD. Recommendations for testing, managing, and treating hepatitis C. 2016. Available at: http://hcvguidelines.org/sites/default/files/HCV-Guidance_July_2016_b.pdf. Accessed 18 Febuary 2018.
20. Aspinall AI, Shaheen AA, Kochaksaraei GS, et al. Real-world treatment of hepatitis C with second-generation direct-acting antivirals: initial results from a multicentre Canadian retrospective cohort of diverse patients. CMAJ Open 2018; 6:E12-8.
21. Dore G, Altice F, Litwin AH, et al. C-edge co-star: efficacy of grazoprevir and elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy. Hepatology 2015; 62(suppl):227A-8A.
22. Dore GJ, Grebely J, Altice F, et al. Hepatitis C virus (HCV reinfection and injecting risk behavior following elbasvir (EBR)/grazoprevir (GZR) treatment in participants on opiate agonist therapy (OAT): CO-STAR part B. Hepatology 2017; 66:112a-13a.
23. Terrault NA, Zeuzem S, Di Bisceglie AM, et al; HCV-TARGET Study Group. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology 2016; 151:1131-1140.e5.
24. Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. In press.
25. Wohl DA, Allmon AG, Evon D, et al. Financial incentives for adherence to hepatitis C virus clinical care and treatment: a randomized trial of two strategies. Open Forum Infect Dis 2017; 4:ofx095.
26. Robaeys G, Grebely J, Mauss S, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis 2013; 57(Suppl 2):S129-37.
27. Del Rio-Valencia JC, Asensi-Diez R, Madera-Pajin R, et al. Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital. Rev Esp Quimioter 2018; 31:35-42.
28. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
29. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370:211-21.